Retrospective study of brentuximab vedotin in combination with bendamustine in relapsed or refractory hodgkin lymphoma.
Phase of Trial: Phase IV
Latest Information Update: 26 Dec 2017
Price : $35 *
At a glance
- Drugs Bendamustine (Primary) ; Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 26 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.